Since the identification of the alternative angiotensin converting enzyme (ACE)2/Ang-(1-7)/Mas receptor axis, renin-angiotensin system (RAS) is a new complex target for a pharmacological intervention. We investigated the expression of RAS components in the heart and kidney during the development of hypertension and its perinatal treatment with losartan in young spontaneously hypertensive rats (SHR). Expressions of RAS genes were studied by the RT-PCR in the left ventricle and kidney of rats: normotensive Wistar, untreated SHR, SHR treated with losartan since perinatal period until week 9 of age (20 mg/kg/day) and SHR treated with losartan only until week 4 of age and discontinued until week 9. In the hypertrophied left ventricle of SHR, cardiac expressions of Ace and Mas were decreased while those of AT1 receptor (Agtr1a) and Ace2 were unchanged. Continuous losartan administration reduced LV weight (0.43 ± 0.02; P < 0.05 versus SHR) but did not influence altered cardiac RAS expression. Increased blood pressure in SHR (149 ± 2 in SHR versus 109 ± 2 mmHg in Wistar; P < 0.05) was associated with a lower renal expressions of renin, Agtr1a and Mas and with an increase in ACE2. Continuous losartan administration lowered blood pressure to control levels (105 ± 3 mmHg; P < 0.05 versus SHR), however, only renal renin and ACE2 were significantly up-regulated (for both P < 0.05 versus SHR). Conclusively, prevention of hypertension and LV hypertrophy development by losartan was unrelated to cardiac or renal expression of Mas. Increased renal Ace2, and its further increase by losartan suggests the influence of locally generated Ang-(1-7) in organ response to the developing hypertension in SHRs.

Department of Cardiovascular Diseases International Clinical Research Centre St Anne's University Hospital and Masaryk University Brno Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovakia

Institute of Normal and Pathological Physiology Centre of Excellence for Cardiovascular Research Slovak Academy of Sciences Bratislava Slovakia

Zobrazit více v PubMed

Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens. 1998;12:301–9. PubMed

Racasan S, Hahnel B, van der Giezen DM, et al. Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension. Kidney Int. 2004;65:575–81. PubMed

Woods LL. Fetal origins of adult hypertension: a renal mechanism? Curr Opin Nephrol Hypertens. 2000;9:419–25. PubMed

Fornes P, Richer C, Vacher E, et al. Losartan’s protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol. 1993;22:305–13. PubMed

Svitok P, Molcan L, Vesela A, et al. Increased salt intake during early ontogenesis lead to development of arterial hypertension in salt-resistant Wistar rats. Clin Exp Hypertens. 2014;22:1–6. PubMed

Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol. 2010;298:F1297–305. PubMed PMC

Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519–27. PubMed

Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3–14. PubMed

Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12–9. PubMed

Ritchie RH, Schiebinger RJ, LaPointe MC, et al. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol. 1998;275:H1370–4. PubMed

Suzuki H, Eguchi K, Ohtsu H, et al. Activation of endothelial nitric oxide synthase by the angiotensin II type 1 receptor. Endocrinology. 2006;147:5914–20. PubMed

Piech A, Dessy C, Havaux X, et al. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res. 2003;57:456–67. PubMed

Vaziri ND, Ni Z, Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension. 1998;31:1248–54. PubMed

Klimas J, Vaja V, Vercinska M, et al. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic Clin Pharmacol Toxicol. 2012;111:279–88. PubMed

Kristek F, Malekova M, Cacanyiova S. Long-term effect of prazosin and losartan administration on blood pressure, heart, carotid artery, and acetylcholine induced dilation of cardiovascular system of young Wistar rats and SHR. Gen Physiol Biophys. 2013;32:235–43. PubMed

Jin X, Xia L, Wang LS, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 2006;6:1948–56. PubMed

Braun MC, Herring SM, Gokul N, et al. Hypertensive renal disease: susceptibility and resistance in inbred hypertensive rat lines. J Hypertens. 2013;31:2050–9. PubMed PMC

Bernstein KE. Views of the renin-angiotensin system: brilling, mimsy, and slithy tove. Hypertension. 2006;47:509–14. PubMed

Kmecova J, Klimas J. Heart rate correction of the QT duration in rats. Eur J Pharmacol. 2010;641:187–92. PubMed

Ochodnicky P, Mesarosova L, Cernecka H, et al. Pioglitazone, a PPARgamma agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol. 2014;730:51–60. PubMed

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8. PubMed

Woods LL, Rasch R. Perinatal ANG II programs adult blood pressure, glomerular number, and renal function in rats. Am J Physiol. 1998;275:R1593–9. PubMed

Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112:805–10. PubMed

Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993;3:1575–82. PubMed

Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–6. PubMed

Tan Z, Wu J, Ma H. Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1-7) in heart and kidney of spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2011;12:413–9. PubMed

Zhong JC, Huang DY, Yang YM, et al. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension. 2004;44:907–12. PubMed

Meng W, Zhao W, Zhao T, et al. Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension. Am J Hypertens. 2014;27:775–82. PubMed PMC

Higashi T, Kobayashi N, Hara K, et al. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol. 2000;35:564–71. PubMed

Kruzliak P, Novak J, Novak M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014;27:3–13. PubMed

Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013;16:289–95. PubMed PMC

Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767–73. PubMed

Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278–87. PubMed PMC

Costa MA, Lopez Verrilli MA, Gomez KA, et al. Angiotensin-(1-7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010;299:H1205–11. PubMed

Dias-Peixoto MF, Ferreira AJ, Almeida PW, et al. The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli. Peptides. 2012;35:196–201. PubMed

Gomes ER, Lara AA, Almeida PW, et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension. 2010;55:153–60. PubMed

Ishizaka N, Griendling KK, Lassegue B, et al. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension. 1998;32:459–66. PubMed

Krieger MH, Di Lorenzo A, Teutsch C, et al. Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest. 2010;90:1573–81. PubMed PMC

Asano N, Ogura T, Mimura Y, et al. Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats. Res Commun Mol Pathol Pharmacol. 1998;100:171–80. PubMed

Samani NJ, Swales JD, Brammar WJ. A widespread abnormality of renin gene expression in the spontaneously hypertensive rat: modulation in some tissues with the development of hypertension. Clin Sci. 1989;77:629–36. PubMed

Yu H, Di Nicolantonio R. Altered age-dependent modulation of tissue renin messenger RNA levels in the spontaneously hypertensive rat. J Hypertens. 1996;14:871–80. PubMed

Liu L, Gonzalez AA, McCormack M, et al. Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hypertensive rats. Am J Physiol Renal Physiol. 2011;301:F1195–201. PubMed PMC

Harrison-Bernard LM, Zhuo J, Kobori H, et al. Intrarenal AT(1) receptor and ACE binding in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol. 2002;282:F19–25. PubMed PMC

Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799–802. PubMed

Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–8. PubMed

Heringer-Walther S, Gembardt F, Perschel FH, et al. The genetic deletion of Mas abolishes salt induced hypertension in mice. Eur J Pharmacol. 2012;689:147–53. PubMed

Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol. 2009;296:F337–46. PubMed

Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006;69:2212–8. PubMed

Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int. 2009;75:1184–93. PubMed

Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296:F398–405. PubMed

Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol. 2014;11:413–26. PubMed PMC

Tesanovic S, Vinh A, Gaspari TA, et al. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30:1606–13. PubMed

Yang JM, Dong M, Meng X, et al. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler Thromb Vasc Biol. 2013;33:1978–85. PubMed

van Twist DJ, Kroon AA, de Leeuw PW. Angiotensin-(1-7) as a strategy in the treatment of hypertension? Curr Opin Nephrol Hypertens. 2014;23:480–6. PubMed

Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol. 2012;63:77–85. PubMed

Influence of gestational salt restriction in fetal growth and in development of diseases in adulthood

Zobrazit více v PubMed

RefSeq
NM_001012006, NM_012512, NM_012544, NM_012642, NM_012757, NM_030985